New hope for rare blood disorder: ravulizumab trial shows promise in china
NCT ID NCT06578949
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed Phase 3 trial tested ravulizumab in 18 adults in China with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The study measured changes in LDH, a marker of red blood cell breakdown, to see if the drug could control the disease. All participants had not previously received complement inhibitor treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ravulizumab
What this could lead to
If successful, ravulizumab could offer a new treatment option for people with PNH in China, helping control red blood cell destruction and reduce symptoms.
What could go wrong
This is a small, single-arm study with only 18 participants, so results may not apply broadly. Ravulizumab requires lifelong treatment and carries infection risks, including meningococcal infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, CN-100730, China
-
Research Site
Guangzhou, 510100, China
-
Research Site
Hangzhou, 310003, China
-
Research Site
Nantong, 226001, China
-
Research Site
Shanghai, 200040, China
-
Research Site
Tianjin, 300020, China
-
Research Site
Tianjin, 300050, China
-
Research Site
Wuhan, 430022, China